Capricor Therapeutics (NASDAQ:CAPR) Now Covered by Analysts at Roth Capital

Investment analysts at Roth Capital initiated coverage on shares of Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) in a research note issued on Tuesday,Briefing.com Automated Import reports. The firm set a "buy" rating and a $31.00 price target on the biotechnology company's stock. Roth Capital's target price suggests a potential upside of 198.94% from the company's current price.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reaffirmed a "buy" rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research report on Monday, March 17th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $30.00 price target on shares of Capricor Therapeutics in a report on Wednesday, May 14th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $35.50.

Capricor Therapeutics Price Performance

CAPR stock opened at $10.37 on Tuesday. Capricor Therapeutics has a 1-year low of $3.52 and a 1-year high of $23.40. The business has a 50-day moving average price of $10.65 and a 200 day moving average price of $13.61. The company has a market capitalization of $473.67 million, a P/E ratio of -9.78 and a beta of 0.85.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.20). The business had revenue of $2.73 million during the quarter, compared to the consensus estimate of $3.16 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. During the same period last year, the firm earned ($0.31) EPS. On average, analysts anticipate that Capricor Therapeutics will post -1.21 earnings per share for the current fiscal year.

Institutional Trading of Capricor Therapeutics

Institutional investors have recently bought and sold shares of the stock. Summit Investment Advisors Inc. increased its stake in Capricor Therapeutics by 54.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. raised its stake in Capricor Therapeutics by 172.8% in the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock worth $64,000 after acquiring an additional 2,947 shares during the last quarter. Virtus ETF Advisers LLC acquired a new stake in Capricor Therapeutics during the 4th quarter worth about $68,000. AlphaQuest LLC purchased a new stake in Capricor Therapeutics during the 4th quarter valued at about $78,000. Finally, New York State Common Retirement Fund increased its holdings in shares of Capricor Therapeutics by 625.0% in the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 5,000 shares during the period. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.